Sarah Chen

Sarah Chen

Technology & Crypto Editor

Sarah Chen leads technology and cryptocurrency coverage at StockTi. With a background in computer science from MIT and five years in fintech equity research, she brings deep technical fluency to her market analysis. Sarah covers earnings, product launches, and regulatory developments across the tech and digital asset sectors. She is a regular contributor to industry panels on blockchain adoption and AI-driven trading.

Technology, Crypto 3,028 articles

Articles by Sarah Chen

Vertiv Completes Strategic Thermal Labs Buyout, Bolstering AI Cooling Portfolio
Technology

Vertiv Completes Strategic Thermal Labs Buyout, Bolstering AI Cooling Portfolio

Vertiv Holdings has closed its acquisition of Strategic Thermal Labs, expanding its AI data-center cooling capabilities. The deal comes amid a 30% Q1 sales surge and an upgraded 2026 forecast.

VRT
SoftBank Shares Tumble on OpenAI Growth Concerns
Technology

SoftBank Shares Tumble on OpenAI Growth Concerns

SoftBank Group shares plummeted nearly 10% after OpenAI missed user and revenue targets, casting doubt on the tech giant's massive AI bet.

ORCL ARM
GitLab Shares Rise on Expanded Anthropic Claude Integration for AI Coding
Technology

GitLab Shares Rise on Expanded Anthropic Claude Integration for AI Coding

GitLab shares climbed 3.2% after expanding its Anthropic partnership, integrating Claude Opus 4.7 into its Duo Agent Platform for enterprise AI coding tools with compliance and audit controls.

GTLB
Classover Shares Surge on BlackRock Stake and EdTech Ranking
Technology

Classover Shares Surge on BlackRock Stake and EdTech Ranking

Classover Holdings shares jumped Tuesday after BlackRock disclosed an 8% Class B stake and the company ranked 122nd on TIME's 2026 U.S. edtech list. KIDZ traded at $1.08, up from $0.97.

KIDZ
Nexera Shares Surge on Gulf Fuel-Tank Security Deal
Technology

Nexera Shares Surge on Gulf Fuel-Tank Security Deal

Nexera Technologies' shares soared 229% after its KeepZone AI unit secured authorization to market fuel-tank protection systems in the Gulf, marking a key step in its shift from retail to security.

XLK
11 Key Drivers Behind Bitcoin Price Fluctuations
Crypto

11 Key Drivers Behind Bitcoin Price Fluctuations

Bitcoin's price is determined by supply and demand, with ETF flows, macro liquidity, regulation, and market sentiment now as influential as the halving event.

MSTR COIN IBIT FBTC
Youxin Technology Soars 150% on $10.8M TikTok Stake Deal
Technology

Youxin Technology Soars 150% on $10.8M TikTok Stake Deal

Youxin Technology shares jumped 149.62% Monday after the company agreed to acquire an 18% stake in TikTok commerce partner YATOP for $10.8 million in stock.

YOU
Apple's Third Co-Founder Sold His Stake for $800, No Regrets at 91
Technology

Apple's Third Co-Founder Sold His Stake for $800, No Regrets at 91

Ronald Wayne, Apple's forgotten co-founder, sold his 10% stake for $800 in 1976. Now worth nearly $400 billion, he says he has no regrets, emphasizing personal liability.

AAPL MSFT GOOGL AMZN META
Interstellar Comet 3I/ATLAS Bears Water Signature from Frigid Exoplanetary System
Technology

Interstellar Comet 3I/ATLAS Bears Water Signature from Frigid Exoplanetary System

ALMA measurements of deuterated water in interstellar comet 3I/ATLAS show a D/H ratio over 40 times Earth's oceans, indicating origin in a far colder system.

XLK
XRP Dips 2.7% to $1.39 Despite Ripple-K Bank Pilot, Stablecoin Focus Caps Rally
Crypto

XRP Dips 2.7% to $1.39 Despite Ripple-K Bank Pilot, Stablecoin Focus Caps Rally

XRP slipped 2.7% to $1.39 on Monday as Ripple's new pilot with K Bank uses stablecoins, not XRP. The broader crypto market also declined, with bitcoin near $76,960.

IBIT
AMD Shares Slide on Downgrade Amid AI Rally Skepticism
Technology

AMD Shares Slide on Downgrade Amid AI Rally Skepticism

AMD shares dropped 3.8% after a Northland Capital downgrade questioned the AI rally's sustainability, while Nvidia and Intel gained.

AMD NVDA INTC
Intellia's CRISPR Therapy for HAE Nears FDA Filing After Late-Stage Success
Technology

Intellia's CRISPR Therapy for HAE Nears FDA Filing After Late-Stage Success

Intellia Therapeutics (NTLA) announced its CRISPR therapy lonvo-z cut HAE attacks by 87% vs placebo in a Phase 3 trial, with 62% of patients attack-free. A rolling FDA submission has begun.

NTLA